Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group

@article{Park2012SorafenibIP,
  title={Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group},
  author={Se Hoon Park and Min Hee Ryu and Baek Yeol Ryoo and Seok Ah Im and Hyuk Chan Kwon and Sung Sil Lee and Sa Rah Park and Bo Young Kang and Yoon Koo Kang},
  journal={Investigational New Drugs},
  year={2012},
  volume={30},
  pages={2377-2383}
}
Purpose To evaluated the efficacy and safety of sorafenib in patients with advanced gastrointestinal stromal tumors (GIST) who failed to previous standard treatments. Experimental Design Thirty-one patients with measurable metastatic GIST who failed both imatinib and sunitinib were accrued. Sorafenib was administered orally at 400 mg twice daily until disease progression or development of intolerance. The primary endpoint was disease control rate (response + stable disease, DCR) at 24 weeks… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
38 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea

  • YK Kang, KM Kim, +5 authors HK Yang
  • J Korean Med Sci 25(11):1543–1552
  • 2010
2 Excerpts

Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3

  • P Reichardt, J Blay, +7 authors P Rutkowski
  • J Clin Oncol 28,
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…